Breatheasy MIIST
Alameda, US · Founded 2019 · Delaware corporation · 6 employees on LinkedIn · 2 known investors
Miist develops inhaled microparticle therapeutics that deliver medicine to the bloodstream in 30 seconds, targeting conditions like migraine, pain, and anxiety where rapid onset is critical. The company is advancing a portfolio of systemic therapies starting with MST-02, a migraine treatment designed to work significantly faster than existing oral medications.
Founders & leadership
Breatheasy MIIST was founded in 2019 by Eric Ezerins and Dalton Signor.
EE
DS
RK
Randy KrebsExecutive
JS
Jeffrey SchusterChief Technology Officer
EA
Evan AlfanoNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$6.4M disclosed across 2 rounds · 2022–2024
▶$6.3MraisedSep 2024 · 11 investors · Other Health CareRule 506(b)
▶$6.3MraisedSep 2024 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Randy KrebsExecutive Officer
- Dalton SignorExecutive Officer, Director, Promoter
- Offering amount
- $8.4M
- Amount sold
- $6.3M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75KraisedOct 2022 · 2 investors · Other Health CareRule 506(b)
▶$75KraisedOct 2022 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Dalton SignorExecutive Officer, Director
- Randy KrebsExecutive Officer, Director
- Evan AlfanoDirector
- Eric EzerinsExecutive Officer
- Jeffrey SchusterExecutive Officer
- Offering amount
- $75K
- Amount sold
- $75K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapBioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
MDI Therapeutics7 shared keywordsMDI Therapeutics is a pharmaceutical company developing small molecule therapies for fibrosis and fibroproliferative diseases, including MDI-2517, an inhibitor of plasminogen activator inhibitor 1 (PAI-1) currently in a Phase 1 clinical study. It operates in the biotech and drug development space.
Maze Therapeutics6 shared keywordsMaze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization. Its pipeline focuses on kidney disease, including programs for APOL1-mediated kidney disease, chronic kidney disease, and phenylketonuria.
Apogee Therapeutics5 shared keywordsApogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care. Its pipeline addresses dermatological, respiratory, and gastroenterological conditions.
Alumis5 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Milestone Pharmaceuticals5 shared keywordsMilestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
Companies competing with Breatheasy MIIST for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Breatheasy MIIST do?
- Miist develops inhaled microparticle therapeutics that deliver medicine to the bloodstream in 30 seconds, targeting conditions like migraine, pain, and anxiety where rapid onset is critical. The company is advancing a portfolio of systemic therapies starting with MST-02, a migraine treatment designed to work significantly faster than existing oral medications.
- Who founded Breatheasy MIIST?
- Breatheasy MIIST was founded by Eric Ezerins, Dalton Signor in 2019.
- Who are Breatheasy MIIST's investors?
- Breatheasy MIIST's investors include FREEFLOW, The Innovation Space.
- How much funding has Breatheasy MIIST raised?
- Breatheasy MIIST has disclosed $6.4M raised across 2 rounds.
- Where is Breatheasy MIIST headquartered?
- Breatheasy MIIST is headquartered in Alameda, US.